Conditions

It has been known for so long that optimal glycemic control in type 1 diabetes can decrease the risk of micro and macrovascular complications, but why is the risk still high despite intensive glycemic control?

If environmental factors such as enteroviruses can trigger beta-cell autoimmunity, then is it possible that a vaccine can reduce the likelihood of developing type 1 diabetes?

How does diabetes affect the risk of developing late-life mild cognitive impairment or dementia?  

The CARMELINA trial demonstrated noninferiority of linagliptin compared with placebo in CV events in high risk people with type 2 diabetes. 

Could older recommendations of maintaining a blood pressure of 140/90 mmHg be misleading in younger adults with type 1 diabetes for cardiovascular risk reduction? 

The results of EMPA-REG OUTCOME Trial assess the role of empagliflozin in patients with type 2 diabetes and atherosclerotic cardiovascular disease.

The lack of studies for children and adolescents with type 2 diabetes has led to an absence of approval of new drugs for this patient population. This study reports findings of Liraglutide for youth.

Myocardial flow reserve plays a significant role as a predictor of cardiac death in patients with diabetes.

New research findings on oral semaglutide vs subcutaneous liraglutide.

The role of 25-hydroxyvitamin D in the progression of type 2 diabetes continues to be explored after a recent study observes diabetes incidence in high risk patients receiving vitamin supplementation.